GlassScriptPhysician profile
Randall Rosenthal
NPI 1700991197
$724.82
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $144 · 2021: $44.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $173.86 | 2019-2020 | |
| Allergan, INC. | $158.39 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $122.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $98.98 | 2019-2020 | |
| Neos Therapeutics, LP | $46.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.02 | 2021 | |
| Neurocrine Biosciences, INC. | $32.29 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $19.07 | 2019 | |
| Lundbeck LLC | $17.46 | 2019 | |
| Shire North American Group INC | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.